DOI: https://doi.org/10.36347/sasjm.2026.v12i06.001

Pages: 584-587

Background: Multiple myeloma (MM) is a heterogeneous plasma cell malignancy characterized by variable clinical presentation, biological behavior, and therapeutic outcomes. Despite significant therapeutic advances, prognosis remains highly variable, particularly according to patient characteristics and disease burden at diagnosis. Real-world data evaluating baseline characteristics, treatment patterns, and early outcomes remain limited in single-center settings. Methods: We conducted a retrospective descriptive study in the Clinical Hematology Department of the 20 August 1953 Hospital, Ibn Rochd University Hospital Center, including all patients diagnosed and followed for MM between January and December 2023. Clinical, biological, and therapeutic data were collected from medical records. Baseline patient characteristics, treatment regimens, response rates, early mortality, and follow-up status were analyzed. Results: A total of 64 patients were included. The median age was 62 years (range: 43–84), and 14% were aged ≥75 years. Male patients represented 65.6% of the cohort. At diagnosis, ECOG performance status was 0–1 in 50% of patients and ≥2 in 44%. Bone pain was the most common presenting symptom, observed in 90% of cases. End-stage renal disease was present in 15% of patients at diagnosis. According to the International Staging System (ISS), 44% of patients had stage III disease. Regarding treatment, standard first-line regimens were predominantly used. Fifteen patients received VTD (bortezomib, thalidomide, dexamethasone), 21% received VCD (bortezomib, cyclophosphamide, dexamethasone), and 10 patients were treated with VRD (bortezomib, lenalidomide, dexamethasone). Treatment response was evaluable in 53 patients. Complete response was achieved in 28.3%, very good partial response in 50.9%, and partial response in 9.4% of patients, resulting in an overall response rate of 88.7%. Treatment failure occurred in 11.3% of cases. Early mortality was observed in 3.2% of